Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

Novartis and Teva represent different pharmaceutical strategies: Novartis is a stable innovator with high margins and strong cash flow, while Teva is executing a turnaround from generics to biosimilars with improving profitability but higher debt. Despite Novartis's superior financial metrics, the article recommends Teva for long-term investors due to its more attractive valuation ratios and strong drug pipeline expected to drive growth in 2027.